Figure 3.

Preventive strategy for thrombotic microangiopathy in kidney transplant (KT) recipients. Modified from Campistol et al. [36]. Modified from Zuber et al. [34], with permission from Elsevier. TMA, thrombotic microangiopathy; KTR, kidney transplant recipient; ESRD, end-stage renal disease; aHUS, atypical hemolytic uremic syndrome; MCP, membrane cofactor protein gene; CFH, complement factor H gene; CFI, complement factor I gene; CFB, complement factor B; anti-FH, anti-complement factor H antibodies; DSA, donor-specific antibody; CMV, cytomegalovirus; LTBI, latent tuberculosis infection; CNI, calcineurin inhibitors; mTOR, mammalian target of rapamycin.